We are thrilled to share that Biocytogen will be attending the 8th Neuroimmunology Drug Development Summit in Boston, MA. Promising clinical data demonstrating the reversal of neuroinflammatory markers in Parkinson’s disease and a growing recognition of TYK2 as a central neuroimmune modulator show that momentum is increasing across the field. Join us, along with over 50 other discovery, preclinical, and translational leaders, in exploring the latest therapies in neurodegeneration and neuroimmune-driven psychiatric diseases.
What is the 8th Neuroimmunology Drug Development Summit
The 8th Neuroimmunology Drug Development Summit is the only meeting dedicated entirely to advancing novel neuroinflammatory targets within the industry. This year’s forum will delve into the emerging glial biology, peripheral immune pathways, and next generation technologies that are accelerating neuroinflammatory target discovery and validation.
Event Overview
Date: April 14th - 16th, 2026
Venue: Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA 02114
Event Schedule
For more information, please download the agenda here.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
Let’s define the future of neuroimmune modulating therapies together, we look forward to meeting you in Boston!
